The Molecule for Better Blood Flow and Longevity

Bryan emphasizes that even exercise won't stimulate NO production if blood sugar is elevated because glucose 'glues' the enzyme that makes nitric oxide into a non-functional conformation. He recommends everyone get a CGM, even without a prescription, to see in real-time how foods affect them. He notes that sugar is sticky like its name implies, binding to hemoglobin (raising HbA1c) and the eNOS enzyme, leading to endothelial dysfunction.

Bryan explains that the dental community is beginning to recognize the importance of the oral microbiome. His research shows that antiseptic mouthwash raises blood pressure and negates the blood-pressure-lowering effect of exercise. Fluoride in toothpaste and drinking water also acts as an antiseptic. Antacids are used by two-thirds of Americans and block gastric NO production, which is crucial for killing pathogens and systemic vasodilation. He stresses stopping these disruptors is the first step, even before adding beneficial habits or supplements.

Bryan stacks these 'hacks': he personally does a 4–5 minute high-intensity workout (push-ups, squats, lunges) followed by an infrared sauna session. He explains that nasal breathing produces NO in the nasal epithelium via mechanoreceptors, matching ventilation to perfusion and lowering blood pressure. Mouth breathing bypasses this, oxygenates the oral cavity, lowers pH, promotes pathogens, and destroys the microbiome. He recommends mouth taping at night only after ensuring no anatomical airway blockage.

Bryan uses an infrared sauna at 170°F for 30 minutes almost daily. He explains heat causes vasodilation as the body tries to cool itself, which is independent of NO but amplified when NO production is primed. He emphasizes that modern people rarely sweat, and sweating is a primary detox route. He always takes a binder before the sauna to bind mobilized toxins, listing activated charcoal, bentonite clay, and spirulina/chlorella as options. He personally does a quick HIIT workout first to boost circulation, then goes directly into the sauna.

Bryan developed this lozenge based on 25 years of research. It is a solid dose form of NO gas that, when dissolved in the mouth, generates about 20 parts per million of NO. He claims it recouples dysfunctional eNOS and helps re-establish the oral nitrate-reducing bacteria. He quantifies the need using a vitamin D analogy: we can't measure blood NO like vitamin D, so his dosing is based on known production rates from healthy physiology. Maintenance is 1–2 lozenges; disease states require more because of ongoing inhibitory factors (sugar, mouthwash, etc.). He relies on healthcare practitioners to adjust dosing.

Bryan's team created InnoBs in response to the popularity and inconsistency of beet products. They ferment the beets to maximize NO-generating potential, remove oxalates (risk of kidney stones), strip the beet pulp and taste, and add electrolytes and mitochondrial ATP. When mixed with a small amount of water, it immediately begins generating NO gas, so it must be taken as a quick shot.

Bryan developed the serum based on the principle that skin fails without adequate blood supply. The dual-chamber pump mixes two components that react to produce NO gas upon application. He claims five peer-reviewed clinical trials show improvements in firmness, fine lines, wrinkles, tone, texture, and clarity. The best results are seen when using systemic NO support (lozenge/powder) plus topical. He is also developing it as a prescription topical for diabetic ulcers and chronic wounds, claiming remarkable healing within weeks to months.

Mentioned as a simple foundational habit alongside diet and exercise. Bryan notes that Americans are overfed, and the data on intermittent fasting and caloric restriction are undeniable. He does not elaborate deeply here but frames it as part of the basics.

Bryan explains that NO meets the definition of a hormone and that his work since 2007 established it as such. He draws a direct parallel to hormone replacement therapy (testosterone, estrogen): if the body can't make the hormone, you give the hormone itself, not a precursor. He contrasts this with the 'hope' that DHEA or pregnenolone will convert to testosterone in someone who is testosterone deficient—calling it laughable. His products are designed to generate authentic NO gas outside the body's compromised pathways, delivering it buccally, orally, or topically. He coined and trademarked the term 'nitriceutical' to distinguish these from typical supplements. This reframing is central to his entire product line and the educational mission he describes.

Bryan says his lab tested nitrate in vegetables from different cities and found up to 50-fold differences. Thus, a consumer might need 3–4 celery stalks in one region or 30–40 in another to get an effective dose. He also notes that many companies market arginine or citrulline without understanding that endothelial dysfunction prevents conversion. He feels an obligation to educate consumers to avoid being defrauded by products that cannot work under real-world physiological conditions.

Bryan cites published research showing that mouthwash use raises blood pressure and erases the protective blood-pressure-lowering effect of exercise. He also associates mouthwash with diabetes and neurodegeneration. He extends the same logic to overly frequent bathing with antibacterial soaps destroying the skin microbiome. His solution is not to buy more products but to stop these disrupting behaviors first, then support the microbiome. He relates this to the dental community's challenge of killing pathogens without harming commensal nitrate-reducing bacteria, which led him to develop a microbiome-targeting toothpaste.

Bryan calls ED the 'canary in the coal mine.' Loss of vasodilation in penile or clitoral vessels mirrors the same endothelial dysfunction in coronary, cerebral, renal, and hepatic vessels. He notes that epidemiological data show higher rates of heart attack, stroke, and all-cause mortality in those with ED. He also points to data suggesting PDE5 inhibitors are associated with lower Alzheimer's incidence, likely due to improved cerebral perfusion.